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S y Therapeutic response in patients with advanced breast cancer is conventionally assessed with
reference to criteria devised by the International Union Agaimst Cancer. Eviden to date suggests, however,
that asse ts of equivalent qualty may be obtained at lower cost from the use of serum markers. The
paper presents estimates of potential cost savings resulting from the use of serum markers in place of
conventional asse t and argues that the sizu of these savigs merits the sablshmet of a randomised
controlled triaL
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At present, there are no reliable predictors of response to
chemotherapy in individual patients with advanced breast
cancer. Even when the chances of response are relatively low
(e.g. 20% response for second-ine chemotherapy), physicans
often feel that no individual patient should be denied the
opportunity to benefit from such therapy. In consequence,
the likelihood of expending clinical resources with no conse-
quent health is considerable. In circumstances in which
patient response cannot be predited in advance, and partic-
ularly when the expected response rate is low, the cost-
effective alternative involves monitoring the progres of the
disease closely, in order to match appropriately the therapy
to disease response or progression.
In patients with advanced breast cancer, the most widely
used criteria for the asssmet of therapeutic response are
those agreed by the UICC - the Interational Union against
Cancer (Hayward et al., 1977). These criteria genlly entail
careful clinil examination, blood tests (haatoogy and
biochenistry) and radiographs while, for a proportion of
patients, isotope bone scans, ultrasound and CT scans and
resonance imaging are required. Proper assesment
of radiographs requires experience in the field and the pro-
cess can be time-consuming. Asemts are gneal made
at 3 month intervals, although some of the more detailed
investigations may be carried out less frequently. Impor-
tantly, a proportion of patients are not asessable by UICC
criteria. Recent clnical research has suggested that changes
in the levels of tumour markers, such as carcinoembryonic
antigen (CEA), in the serum ofpatients with advanced breast
cancr may also be used to monitor therapeutc response
(Dnistria et al., 1991; Robertson et al., 1991a), as may
glycoprotein markers such as CA15-3 (Tondini et al., 1988;
Robertson et al., 1990), MCA (Cooper et al., 1989; Laurence
et al., 1991) and BCM (Daly et al., 1992). These alternative
methods of monitoring, however, have yet to gain widesp-
read acceptance, and no single marker appears ideal or
sufficient for breast cancer when used in isolation from
others.
Earlier studies undertaken in the Nottingham Breast
Cancer Unit have allowed the construction of a biochemical
index for the measurement of therapeutic response in patients
with systemic breast cancer. This index was constrcted ret-
rospectively (Wlliams et al., 1990) and then tested prospec-
tively on new patients. Using CA15-3, CEA and erythrocyte
sedimentation rate (ESR) in combination, 93% of patients
with systemic breast cancer were assessable by the
biochemical index for response to either hormone therapy or
chemotherapy (Dixon et al., 1991; Robertson et al., 1991b).
This proportion is at least equivalent to that asable using
the UICC criteria (Hayward et al., 1977). In patients fol-
lowed for response by the UICC criteria, the rsonse
statuses at 6 months were highly and significntly correlated
with the biochemical index at 2, 4 and 6 months.
Although these data sugest that the establshed UICC
criteria and serum markers assay yield broadly equivalent
assessment outcomes, the latter method posseses potential
advantages over the former. First, it is more objective and
reproducible. Second, it is a leks intnrive form of investiga-
tion from the patient's perspective. Third, it gives an earlier
measure of progression than the UICC criteria which usually
reflect strctural damage to tissue, e.g. lytic bone metastases
fractures. Fourth, and most importantly in view of the cur-
rent economic climate, it is likely to represent a far cheaper
form of monitoring than the current method.
In the absence of evidence from a large-scale triaL the
relative cost-effeciveness of guidanc using serum markes as
opposed to UICC criteria must remain unproven. However,
such a trial would itself prove expensive to mount and, in
order to support the case for its implementation, an ex ante
'order-of-magnitude' estimate of potential cost savings is
required. The present paper attempts to provide this inform-
ation, on the basis of a implfied model of the dinical
processes involved.
Mdtho1
The cost savings projection relies on data from two sources.
These are, first, broad retrospective clnical parameters estab
lshed from accumulated research undertaken in the Nottin-
gham Breast Cancer Unit and, second, the unit costs of the
components of monitoring, hormone therapy and chemo-
therapy icurred by the City Hospital, Nottingham. Two
monitonng protocols are estabished, based upon current
(UICC) and potential (markers) practice, and each is costed
on an annual basis.
For UICC assessment at diagnosis of metastases, a full
blood count, biochemistry, liver ultrasound, chest radiograph
and a bone scan are required for all patients. For the 60%
who are likely to record a positive bone scan before treat-
ment, skeletal radiographs of abnormal bone scan sites will
also be necessary for subsequent assessment of therapeutic
resonse. These patients will receive follow-up assesmnents at
3 month intervals, entailing full blood counts, biochemistry,
liver ultasounds, chest radiographs and skektal surveys. For
the 40% of patints for whom the pretreatment bone scans
are not diagnostic of bone metastases, subsequent assess-
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March 1995.ments will require bone scans rather than skeletal surveys.
Additional full blood counts and biochemistry will be
required before each cycle of chemotherapy, which will be
between therapeutic asssment vits.
For serm marker assesent at diagnosis, we presume
that a chest radiography, bone scan and liver ultrasound
would accompany the marker measurement. In reality, it is
likely that only one imagi g test showing metastases would
be required, and a patient's signs or symptoms would suggest
the most appropriate form of investigation. However, to
avoid overstatng the potential cost savings from the use of
serum markers we shall include the use of all three imagi
modalities for all patients. For follow-up assesments at 2, 4,
6, 9 and 12 months, only serum marker measures would be
required.
Full blood counts and biochemistry will be required before
each cycle of chemotherapy in both methods of assessment,
although these are costs associated with therapy rather than
assessment per se. In therapies guided by serum markers, it is
assumed that skeletal radiographs would be used only to
plan radiotherapy.
The gross cost savings estimated in this study arise from
two sources. First, the serum markers assessment protocol, as
specified above, emerges as being cheaper than the esta-
blished UICC protocol for the monitoring of any given
tumour and irrepective of any subsequent therapeutic
intervention. Second, evidence suggests that serum markers
at 2-4 months can accurately predict UICC assessment at 6
months (Robertson et al., 1991b). Accordingly, we shall
presume that the use of the serum markers protocol in place
of UICC would permit the diagnosis of progressive disease at
some earlier stage and would thus facilitate the earlier dis-
continuation of ineffective therapies. This, in turn, will yield
savings in the cost of drugs administered.
As noted earLer, the projections rely upon experience
accumulated in one particular institution. As information
from a variety of clinical settings has yet to be generated, a
simple ad hoc sensitivity analysis is employed to reveal a
plausible range of costs saving to be anticipated.
Res
Table I displays the alternative protocols described above
and includes the projected costs per patient over the first year
following diagnosis. As may be inferred, UICC is approx-
imately 50% more expensive than serum markers and the use
of the latter in place of the former would entail monitoring
cost economies of £189.07 per patient. For the second and
subsequent years, annual costs of UICC and serum markers
assessent would amount to £304.62 and £123.50, respec-
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tively, representinig a cost difference of £181.12. To gauge the
sensitivity of these findinp to variations in patient charac-
teristics, we allow the investigation proportions which do not
apply to all patients to vary by ± 10%. This prduces a
UICC cost range of £417.33-£465.81 in the first year, imply-
ing potential cost economies using serm markers of £164.83
(pessimistic assumption) to £213.31 (opfimistic assump-
tion).
The permutations ofdrugs regulay employed in hormone
therapy and chemotherapy following diagnosis of metastatic
breast cancer are extremely complex. Table II therefore dis-
plays the costs and cost savinp related to stylised regimens
of hormone therapy, first-line and second-lne chemotherapy.
The selection of hormone therapy will be influenced by the
Imenopausal status of the patients, and the pattern indicated
reflects the recent patient distribution at the study site. Vir-
tually all patients will receive a trial of hormone therapy at
some period. Second-ine endocrine therapy will be used for
Table I Costs oftherapy, per case per year
Percentage of Cost per
Type patints receiving month (f) Totalcost (f)
Hormone therapy
Pre-nopausal (33% ofpatients)
Zoladex 100 105.75 1269.00
Tamoxifen 100 1.47 17.64
Megace 67 3030 243.61
Post-menopausal (67% ofpatens)
Tamoxifen 100 1.47 17.64
Megace 67 30.30 243.61
Lentaron 33 80.42 318.46
Weighted sum 893.39
Savings, assuminng 50% progress and 2 months saved 74.45
First line chemotherapy
CMF 60 19.92 143.42
mMM 40 259.86 1247.30
Antiemetics 100 30.40 364.80
Sum 1755.53
Savings, assuming 50% progress and 2 months saved 146.29
Second-ln chmotherapy
Epirubicin 40 321.39 1542.65
IMM 60 259.86 1870.96
Antiemetiks 100 30.40 364.80
Sum 3778.41
Savings, a 80% progress and 2 months saved 503.79
Tae I Projectod costs of ssessIent per patient in the first year
Percentage ofpatins receivin amssc.st, by month
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most, except where the disas is pr very rapidly.
We esimate that at least two-thirds will receive second-line
hormone therapy. Third-line hormone therapy is usually
rsrved for patients with tumours which have been shown to
be endocrine sntive. Fifty per cent of patients respond or
have static dises to first-line hormone therapy, of whom
two-thirds will have a further period of remission in second-
line endocrine therapy (Robertson et al., 1989), i.e. one-third
of the entire patient group. These patients should receve a
trial of third-line endocrine therapy, and we have therefore
used this number in our calculations. This is almost certainly
an underestimte as, in elderly patients, endocrine therapy is
often ni even when the chances of remission are
small.
The alternative first-line chemotherapy regimens are cyc-
lophosphamide, methotrexate and 5-flurouracil (CMF) or
mitoxantrone, methotrexate and mitromycin C (MMM).
MMM would only be used as first-line chemotherapy for
advanced breast cancer if CMF had been used as adjuvant
therapy. For chemotherapy-naive patients, the much cheaper
CMF would be preferred as the first-line regimen on diag-
nosis of advanced disease. The choice of second-ie
chemotherapy is related to which agents were employed in
first-line therapy.
As indicated, these savings are estumated on the basis of
the proportion of patients in whom the tumours will be
progressng and for whom the eariier assessment facilitated
by serum markers will lead to arlier treatment discontinua-
tion. We have presumed a 2 month saving in each case.
Given the variation in the length of courses of therapy, we
have sandardised all unit costs onto a monthly basis. The
average cost of antiemetics in both cases has been estimated
from the empirical observation that 40% ofpatients required
ondansetron with dexamethasone (at £75.6 per cycle), 40%
received maxolon (at only 0.33 p per course), while the
mainder received no antiemetic therapy. The antiemetic
cost included in Table II is thus the weighted average of the
above.
To test the ensitivity of these results to parameter varia-
tion, we might vary, by 10%, first the proportion ofpatients
receiving the cheaper drugs (implying corresponding changes
to the proportion receiving the more expensve) and, second,
the proportion of patients progesng as identified earlier by
the serum markers. These assumptions yield treatnt sav-
ings per patient per year in the range £67.61-£81.16 for
hormone therapy, £118.71-£176.76 for first-line
chemotherapy and £448.09-£5i60.66 for second-he
chemotheapy.
Median patient survival after the diagnosis of relapse is
around 2 years (Richards et al., 1993). To obtain some
notion of aggregate potential cost saving over a patient's
expected lifetime, we shall assume that a patient with diag-
nosed metastatic breast cancer is monitored over 2 years
usng serum markers as opposed to the UICC criteria. Most
units will exhaust hormone therapy where appropriate for
patients with metastatic disas before tuming to
chemotherapy although, in some patients, chemotherapy will
be used initially. For the purposes of this ilustration, we
presume that hormone therapy is the systemic anti-cancer
therapy for the first 12 months, and is thereafter replaed by
chemotherapy. By 16 months, patients will be equally divide
between first-ie and second-line chemotherapy. By 20
months, 90% will have moved to second-ine, the proportion
rising to 100% by 24 months. For each time period, the
estimated cost savigs apply. For the regimen outlined in
Table II, the expected cost savings per patient, which accrue
both to the use of serm markers and to economi in drug
use, win amount to £876.93 over 2 years. For the ± 10%
sensitivity range, savings will vary between £773.79 (kast
favourable asptions combined) and £981.45 (most
favourable assnptions combined).
These savings estimates may easily be translated into
national figures. Approximately 14000 women die of breast
cancer each year in England and Wales (Office ofPopulation
Censuses and Surveys, 1993), implying that, in the seady
state, and that all patients follow the above
regimen, half ofthe 2 year savings will accrue to 28 000 cases
each year. Thus, the estimated average savings at a national
level would accordingly lie in the range £10.83-£13.74 mil-
lion per annum. With perhaps more realism, however, a
recent study of clnical practice (Gregory et al., 1993) has
suggeted that only some 50% of patients with metastatic
breast cancer actually receive any chemotherapy. Reworking
the above cakclation under the assumption that the
economies in chemotherapy are only available for half the
patients, we estimate that annual cost savings at a national
level would lie in the range £8.16-£10.35 million.
Large though the projected savings are, it must be apprec-
ated that they remain underestimates even under the model's
most imistic assumptions. The data refer only to the
most basic financial costs of assessent and therapy and,
among salient omissions, are the following. First, the
estimated costs of the chemotherapy regimens inchlde those
of patient preparation but exclude hospital overheads.
Second, the assesnt protocols are costed only on the basis
of the tests admiistered and exclde both the input of the
supervising physician (which is likely to be more considerable
in the UICC case) and the cost of a radiologist x ienced
in ing therapeutic response. Third, a reduction in the
number of courses of chemotherapy would also economise
on the number of routine investigations necusary to assess
patients before each course. Finally, savings on in-patient
costs as a result of earlier discontinuation of treatment
whenever appropriate have not been included, and studies
conducted in other hospitals sugget that such costs are a
major determinant of the overall cost of treatment (de Kon-
ing et al., 1992; Hurley et al., 1992; Richards et al.,
1993).
This having been said, it is important to stress that the
model-building approach adopted above cannot, in the final
analysis, hope to supplant important evidence which would
only be obtainable in a future trial context. Among the
'unknowns' at this stage are the following. First, we have
presumed that our interpretation of the UICC criteria is the
appropriate definition of current cinical practice. Whethr
the full range of investigations encompassed by the UICC
criteria is, in fact, clinially the most appropriate is beyond
the scope ofthis paper, although it is evident that, at institu-
tions where a more restricted interpretation of the criteria is
employed, the potential cost savings of serum marker
monitoring would be smaller. Second, there could exist cir-
cumanc under which these alculations overstate the true
economies of serum marker monitoring. For example, closer
monitoring might lead, in practice, to an earlier switch from
(generally cheap) hormone therapy to (generally more expen-
sive) chemotherapy, although such cost increases might even-
tually be offset by improved quality of life.
Related to this point is the fact that the model has not
been extended to includ the cost implications of third- or
fourth-line chemotherapy regins, because their use in Not-
tingham is largely confined to the palliation of symptoms in
only a few, quite specific cases. Despite limited evidence of
efficacy, other hospitals might well make routine use of such
egimen, which are generally more expensive than first- and
second-lin therapy. However, the model suggts that cor-
responding saving should be available for third- and fourth-
lie chemotherapy, in cases where it is employed more
regularly, and, overalL this would tend to increase the
economies available to the serum markers regimen.
Third, our cost simulation has been based on an assumed
survival time of 2 years. Patients surviving longer than this
median will naturally offer scope for greater cost economies,
while earlier deaths would result in smaller cost savings. The
final net effect will be determined by the ex tally
observed survival distribution and, other thin being equal,
a skew to the right would entail smaller potential savings.Cst Cs in gdIng mu cw apy
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Fourth, it is conceivable that, in particular cases, addi-
tional investigations would be required for the purposes of
monitoring therapy, over and above those suggested by our
models of the UICC and serum marker criteria. These addi-
tional potential costs cannot be accommodated in the model,
in the absence of experimental data, although, unless the use
of further investigations is disproportionate between criteria,
there seems no reason to believe that such costs would affect
the scale of estimated cost savings. Finally, it is possible that
different hospitals would make use of drugs different from
those typically employed in Nottingham and cost savings
would be smaller were cheaper drugs to be employed in
chemotherapy. For example, the use of doxorubicin
treatments, at £221.73 per month, in place of MMM and
epirubicin, would reduce the first- and second-line
chemotherapy savings in the Table II model by around 11%
and 21% respectively. On the other hand, other centres
might currently be employing more expensive drug regimens
than Nottingham, in which case the savings from serum
markers would be greater.
It must again be stressed that our estimates ofcost savings
are valid only within the confines of the model's assumptions
and the data collected at Nottingham. It accordingly remains
to be demonstrated more rigorously that the outcomes of
serum marker assessment are at least as reliable as those of
UICC and that our cost estimates are applicable to hospitals
in general. Such a demonstration would only be possible as a
result of a multicentre, randomised controlled trial, compar-
ing two groups of patients treated on the basis of either
UICC or tumour marker assessment. The magnitude of the
projected cost savings certainly supports the case for such a
trial; indeed, based on our estimates, even a large, multicen-
tre trial could pay for itself in a matter of weeks.
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